Person:
KARAASLAN, ELİF

Profile Picture
Status
Kurumdan Ayrılmıştır
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
ELİF
Last Name
KARAASLAN
Name
Email Address
Birth Date

Filters

Browse subject tree
2016 - 20208
Reset filters

Settings

Author: DOYMAZ, MEHMET ZIYA ×

Search Results

Now showing 1 - 8 of 8
  • Thumbnail Image
    PublicationOpen Access
    Discordance between Serum Neutralizing Antibody Titers and the Recovery from COVID-19
    (2020-09-25T00:00:00Z) Koç, Mm; Kalkan, Yazıcı; Çetin, Nesibe Selma; Doymaz, Mz; Sümbül, B; Durdu, B; YAZICI, MERVE; MERİÇ KOÇ, MELİHA; ÇETİN, NESİBE SELMA; KARAASLAN, ELİF; OKAY, GÜLAY; DURDU, BÜLENT; SÜMBÜL, BİLGE; DOYMAZ, MEHMET ZIYA
    The recent pandemic of COVID-19 has caused a tremendous alarm around the world. Details of the infection process in the host have significant bearings on both recovery from the disease and on the correlates of the protection from the future exposures. One of these factors is the presence and titers of neutralizing Abs (NAbs) in infected people. In the current study, we set out to investigate NAbs in the recovered subjects discharged from the hospital in full health. Serum samples from a total of 49 documented consecutive COVID-19 subjects were included in the study. All the subjects were adults, and serum samples collected during the discharge were tested in viral neutralization, enzyme immunoassay (EIA), and Western immunoblot tests against viral Ags. Even though a majority of the recovered subjects had raised significant NAb titers, there is a substantial number of recovered patients (10 out of 49) with no or low titers of NAbs against the virus. In these cohorts as well as in patients with high NAb titers, viral Ag binding Abs were detectable in EIA tests. Both NAb titers and EIA detectable Abs are increased in patients experiencing a severe form of the disease, and in older patients the Ab titers were heightened. The main conclusion is that the recovery from SARS-CoV-2 infection is not solely dependent on high NAb titers in affected subjects, and this recovery process is probably produced by a complex interplay between many factors, including immune response, age of the subjects, and viral pathology.
  • No Thumbnail Available
    PublicationMetadata only
    Evaluation of CCHFV nucleoprotein as diagnostic tool in ELISA
    (2017-09-10) ÇETİN, NESİBE SELMA; KARAASLAN, ELİF; YAZICI, MERVE; Hasanoğlu, Sevde; KALKAN, AHMET; KILIÇ, ALİ OSMAN; ÖZDARENDELİ, AYKUT; DOYMAZ, MEHMET ZİYA; ÇETİN, NESİBE SELMA; KARAASLAN, ELİF; YAZICI, MERVE; DOYMAZ, MEHMET ZIYA
  • No Thumbnail Available
    PublicationMetadata only
  • No Thumbnail Available
    PublicationMetadata only
    Investigation Of The Cellular And Humoral Immune Responses Against Nucleoprotein Of Crimean Congo Hemorrhagic Fever Virus (CCHFV)
    (2019-05-10) ÇETİN, NESİBE SELMA; KARAASLAN, ELİF; DOYMAZ, MEHMET ZİYA; KILIÇ, ALİ OSMAN; ÇETİN, NESİBE SELMA; KARAASLAN, ELİF; DOYMAZ, MEHMET ZIYA
  • No Thumbnail Available
    PublicationMetadata only
    INVESTIGATION OF HUMORAL RESPONSE RAISED AGAINST BACTERIALLY EXPRESSED NUCLEOPROTEIN OF CRIMEAN CONGO HEMORRHAGIC FEVER VIRUS
    (2016-04-27) KARAASLAN, ELİF; ÇETİN, NESİBE SELMA; KILIÇ, ALİ OSMAN; DOYMAZ, MEHMET ZİYA; KARAASLAN, ELİF; ÇETİN, NESİBE SELMA; DOYMAZ, MEHMET ZIYA
  • No Thumbnail Available
    PublicationMetadata only
    Immunological Characteristics of Nonstructural Proteins of Crimean-Congo Hemorrhagic Fever Virus
    (2017-09-10) KARAASLAN, ELİF; DOYMAZ, MEHMET ZİYA; KARAASLAN, ELİF; DOYMAZ, MEHMET ZIYA
  • No Thumbnail Available
    PublicationMetadata only
    Detailed Immonological Analysıis of Recombinant Crimean Congo Hemorrhagic Fever Virus Nucleoprotein
    (2019-04-28) KARAASLAN, ELİF; ÇETİN, NESİBE SELMA; Hasanoğlu, Sevde; KILIÇ, ALİ OSMAN; KALKAN, AHMET; ÖZDARENDELİ, AYKUT; DOYMAZ, MEHMET ZİYA; KARAASLAN, ELİF; ÇETİN, NESİBE SELMA; DOYMAZ, MEHMET ZIYA
  • No Thumbnail Available
    PublicationMetadata only
    Comparison of antibacterial activities of polymyxin B and colistin against multidrug resistant Gram negative bacteria
    (2019-07-11T00:00:00Z) Doymaz, MEHMET ZİYA; Karaaslan, ELİF; DOYMAZ, MEHMET ZIYA; KARAASLAN, ELİF
    Background: Polymyxin B and colistin have similar structures except for one amino acid. Usually, physicians choose either polymyxin B or colistin for treatment of infections caused by multidrug-resistant (MDR) organisms. The preference is based on previous experience. Not much data are found in the literature comparing the two drugs against the same microorganisms. In this study, we compared in vitro antimicrobial activities of the two polymyxins against a panel of highly resistant and susceptible microorganisms. Methods: Eighty-nine clinical isolates (27 Klebsiella pneumoniae, 31 Acinetobacter baumannii and 31 Pseudomonas aeruginosa) were tested in broth microdilution assays. Time-kill curve experiments were carried out on selected isolates. Results: Significantly lower MICs for polymyxin B than for colistin were found against all species tested including K. pneumoniae (p < .02), A. baumannii (p < .001) and P. aeruginosa (p < .01). The low MICs caused a change in categorical interpretations of only two K. pneumoniae and two P. aeruginosa. Similar results were obtained in time-kill curve experiments with both susceptible and resistant clinical isolates. Conclusions: Significantly lower MICs were found for polymyxin B against three of the most critical MDR species. Even though differences in categorical interpretations were not striking, lower MICs might be a critical consideration in clinical management of select cases where the concentration of these toxic antibiotics matters because of underlying co-morbidities. These results provide support to previous suggestions that re-consideration of breakpoint interpretations for polymyxins might be needed.